MedTrace Logo

Prevention of Postoperative Nausea and Vomiting (PONV) in Surgical Patients

NCT00757822 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 216

Last updated 2016-05-13

Study results available
· View outcomes & findings →

Summary

This study will compare two different drug regimens (oral dronabinol versus intravenous ondanseteron) for the prevention of post-operative nausea and vomiting (PONV).

Conditions

  • Postoperative Nausea and Vomiting

Interventions

DRUG

Dronabinol

Dronabinol (5mg) will be administered orally (p.o.) 20-60 min pre-operatively.

DRUG

Ondansetron

Ondansetron (4mg) will be administered intravenously (iv) intraoperatively in those patients not receiving Dronabinol.

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Sue A Theus, PhD · Central Arkansas Veterans Healthcare System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2013-12-31
Completion
2015-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00757822 on ClinicalTrials.gov